

RESEARCH PAPER

Detection of *Helicobacter pylori* and its Antimicrobial Susceptibility Pattern from Gastric Biopsy Specimens

Nusrat Noor Tanni¹, Sharmeen Ahmed², Shaheda Anwar², Saifa Kismat²,
Mohammad Mosiur Rahman³, Mohammad Abdur Rahim Miah⁴

¹Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh; ²Department of Microbiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; ³Department of Pathology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; ⁴Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Abstract

Background: Early detection of *Helicobacter pylori* (*H. pylori*) infection is essential for its treatment. Resistance to amoxicillin, clarithromycin and metronidazole has been on the increase in many countries. Phenotypic resistance is correlated with treatment failure. So, there is an urgent need to explore sensitivity of other antibiotics, such as levofloxacin to combat *H. pylori* infection.

Objective: The study was aimed to detect *H. pylori* from gastric biopsy samples and its susceptibility profile to commonly used antimicrobial drugs.

Methods: Gastroduodenal biopsy specimens were collected from 143 adult dyspeptic patients during March 2018-February, 2019, who attended the outpatient department of gastroenterology, Bangabandhu Sheikh Mujib Medical University (BSMMU) and Dhaka Medical College Hospital (DMCH), for endoscopy. *H. pylori* was identified by rapid urease test (RUT), *ureC* gene PCR, histological staining (Giemsa) and culture. From culture isolates antimicrobial susceptibility of clarithromycin, levofloxacin, amoxicillin and metronidazole were detected by disk diffusion method.

Results: The highest rate of *H. pylori* infection was found in the age group between 41-50 years (25.5%). According to case definition, *H. pylori* positive cases were 47 (32.9%) and *H. pylori* negative cases were 96 (67.1%). Thirty five *H. pylori* positive samples were subjected to culture and only 10 (28.6%) were positive. Among 10 culture positive *H. pylori* isolates, clarithromycin exhibited 20% resistance, levofloxacin 30%, metronidazole 30% and no resistance found to amoxicillin.

Conclusion: PCR based assays can be an alternative rapid approach for the detection of *H. pylori*. In this study, levofloxacin showed high resistance, a further larger study is required to confirm this finding.

Keywords: Rapid urease test, *ureC* gene PCR, Clarithromycin, Levofloxacin

Introduction

Helicobacter pylori colonised the stomach of over half of the world's population but only 10-20% of infected persons become symptomatic.¹ The most common symptom of *H. pylori* infection is dyspepsia and prevalence of *H. pylori* infection in adult dyspeptic patient in India was 32.9%.^{2,3} Prevalence of *H. pylori* infection was found to be high (60.2%) in Bangladesh, which is related to overcrowding and poor sanitary conditions.⁴ *H. pylori*

infection causes gastritis, duodenal ulcer, gastric carcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma.⁵ Detection and treatment of *H. pylori* infection is recommended in all symptomatic individuals in order to prevent *H. pylori* induced diseases.⁶

Several invasive and noninvasive techniques are currently used for detecting *H. pylori* infection, such as rapid urease test (RUT), urea breath test, culture, PCR, serological tests and histopathology with their specific advantage and disadvantage.⁷ Gastric biopsy specimens obtained during endoscopy are best sample for *H. pylori* isolation.⁸

Rapid urease test is the most useful invasive test for the diagnosis of *H. pylori* infection, sensitivity and

*Correspondence: Nusrat Noor Tanni, Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh
e-mail: nusratnoortanni@gmail.com
ORCID: 0000-0001-7509-0424

specificity of various RUT tests as primary diagnostic tests vary between approximately 80 -100% and 97 -99%.^{9,10} Other than detection of *H. pylori*, histopathology also allows assessment of morphological changes of the gastric mucosa due to *H. pylori* infection.¹ Sensitivity and specificity of histology varies from 53% to 90%, depending on the clinical setting, density of colonisation and experience of the histopathologist.¹¹

Many polymerase chain reaction (PCR) methods provides excellent sensitivity and specificity, as compared with other conventional tests for *H. pylori* detection from clinical specimens.^{12, 13} *ureC* gene is more appropriate than other genes for detection of *H. pylori* from clinical specimens. The *ureC* gene later renamed as *glmM* gene, a housekeeping gene that encode the phosphoglucosamine mutase (*glmM*), which is unrelated to urease production.¹²

Although culture of *H. pylori* from gastric biopsy is the gold standard for antibiotic susceptibility testing, sensitivity of culture were lower as 55–73% in some studies, due to strain fastidiousness, effects of treatment, overgrowth of contaminating microorganisms etc.^{14, 15} In routine practice, the detection of antibiotic resistance is mainly based on phenotypic methods: disk diffusion method, E-test or the agar dilution method.¹⁴

A triple therapy containing a proton pump inhibitor and two antibiotics, amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ), is the standard first-line treatment of *H. pylori* infection in populations with less than 15–20% clarithromycin resistance.⁶ In Bangladesh, clarithromycin based regimen is the first line *H. pylori* eradication therapy.¹⁶ After failure of first line therapy, levofloxacin containing triple therapy is recommended as second line treatment.¹⁷

Clarithromycin, metronidazole and amoxicillin resistance rates had been reported to be 58.8%, 83.3%, 72.5% and 36.0%, 89.0%, 37% in India and Pakistan respectively.^{18, 19} High resistance rate of *H. pylori* to levofloxacin (73.2%) has been reported in north India.²⁰ In Bangladesh 39.3% clarithromycin, 94.6% metronidazole, 3.6% amoxicillin and, 66.1% levofloxacin resistance rate had been reported in gastritis patients.²¹

As a recommendation from Maastricht IV Consensus Report, *H. pylori* culture and antibiotic susceptibility

testing should be performed if primary resistance to clarithromycin is higher than 20% in a given geographical area or after the failure of second-line treatment.²²

The present study was aimed to detect *H. pylori* by different invasive methods (histology, RUT, culture, and PCR) from gastric biopsy specimens, compare the sensitivity and the specificities of different *H. pylori* detection methods and, evaluate the resistance pattern to - clarithromycin, amoxicillin, metronidazole and levofloxacin in *H. pylori* by disk diffusion method.

Materials and Methods

This cross sectional, observational study was conducted over a period of 12 months starting from March 2018, at the department of microbiology & immunology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. The study was ethically approved by the Bangladesh Medical Research Council, Dhaka.

Samples were collected from 143 adult patients, who presented with dyspepsia for more than 1 month, in outpatient department of gastroenterology, BSMMU and Dhaka Medical College Hospital (DMCH).²³ Patients above 65 years of age having severe medical or surgical illness, or history of intake of proton pump inhibitors, non-steroidal anti-inflammatory drugs, colloidal bismuth compounds, or antibiotics for eradication of *H. pylori* over the past four weeks of enrolment were excluded from the study.²⁴

After obtaining written informed consent, a total of four pieces of gastric tissue were collected from lesion and surrounding sites of gastric antrum and body. First specimen was inoculated immediately into a screw capped bottle containing RUT media, change in the colour from yellow to pink within twenty four hours after incubation at 37°C indicate positive test. Second biopsy specimen was collected in Stuart transport media for culture. Third biopsy specimen was collected in PBS for PCR and stored at -20°C until DNA extraction. Fourth specimen was fixed in 10% buffered formalin and transported to the department of pathology, BSMMU for histological examination.

A patient was considered as *H. pylori* positive case, if he/ she had, (i) Positive *H. pylori* culture²⁵ and / or (ii) At least two of the other three tests were positive.²⁶

Culture and sensitivity testing: Gastric tissue was minced manually and placed on brain heart infusion

agar (Oxoid, Ltd, Basingstoke, Hampshire, United Kingdom) supplemented with 10% sheep blood, Vitamino Growth Supplement (Twin Pack) (Hi Media, India), and Campylobacter selective supplement (Hi Media, India).²⁷ The plates were incubated at 37°C in an anaerobic jar with a gas generation pack (CO₂ Gen Sachet™, Oxoid, USA), and examined on 3rd day. *H. pylori* colonies were identified based on morphology (small, round, convex, translucent colonies) (figure1), Gram staining (curved rod), positive catalase, urease and oxidase test. If no growth observed on 3rd day, the plates were rechecked on every alternative day up to 7 days.




Figure 1: Growth of *H. pylori* in Brain heart infusion agar supplemented with 10% sheep blood, vitamino growth supplement and campylobacter selective supplement.

For antibiotic sensitivity testing, bacterial suspension was prepared and compared to McFarland 3 turbidity standard and inoculated in Mueller-Hinton agar plate supplemented with 10% sheep blood. After placing antibiotic disks, agar plates were kept at 37°C for 72 hours under microaerophilic condition. Zone Diameter of clarithromycin (15 µg/disk) ≤18 millimeter (mm)²⁸, levofloxacin (5 µg/disk) <17mm²⁹, metronidazole (5 µg/disk) <16 mm²⁸, and amoxicillin (10 µg/disk) ≤18mm³⁰ were considered as resistant.

DNA was extracted from gastric tissues using QIAmp DNA mini kits (Qiagen, Hilden, Germany) according to the manufacturer's instruction. The *ureC* primer sequences were - *ureC*-F 52 -AAGCTTTTA

GGGGTGTAGGGGTTT-32 , *ureC*-R 52 - AAGCTTACTTTCTAACACTAACGC-32 . The DNA were denatured at 94°C for 5 minutes, followed by 35 cycles at 93°C for 1 minute, 55°C for 30 seconds, 72°C for 1 minute and final extension at 72°C for 10 minutes. Electrophoresis of the amplified products were done in 2% agarose gel at 110V for 42 minutes, amplified product were 294 base pair (figure 2).¹²



Figure 2: Agarose gel electrophoresis analysis showed amplified DNA product of *ureC* gene PCR (294 base pair). Lane 2, 6, 7, 8: positive. Lane 1, 3, 4 and 5: negative. Positive control: *ureC* gene positive *H. pylori*, Negative control: Amplified product of PCR without DNA

Data were re-checked and analysed using SPSS software version-23 (IBM, Armonk, New York). Sensitivity and specificity of different detection methods were calculated considering case definition of *H. pylori* positive cases as gold standard.

Results

A total of 143 gastric biopsy specimens were collected, rapid urease test, PCR amplification of *ureC* gene and histopathological examination were performed in all cases. Cultures for *H. pylori* were done only in 104 cases, as rest of the samples were not properly collected and transported for culture.

Among 143 cases, *H. pylori* was detected in 66 (46.2%) and 36 (25.2%) cases respectively by RUT and histological staining. *ureC* gene was detected in 42 (29.4%) cases, however cultures were positive only in 10 (9.6%) cases. According to the case definition of *H. pylori* positive case, out of 143 patients, 47 (32.9%) were considered as *H. pylori* positive cases. Among 47 *H. pylori* positive cases, 43 (91.5%) were found to be positive by RUT followed by *ureC* gene PCR 42 (89.3%) and histological staining 35 (74.4%). Whereas, 35 *H. pylori* positive samples were subjected to culture and only 10 (28.6%) of them yield culture positive (table I).

Table I: Rate of positivity of *H. pylori* by combination of rapid urease test (RUT), *ureC* gene PCR, culture and histological staining as per case definition (n=47)

Name of tests	Positive cases	Percentage
RUT, PCR, histology and culture	8	17.0
RUT, PCR and histology	18	38.3
RUT, PCR and culture	2	4.3
RUT and PCR	10	21.3
RUT and histology	5	10.6
PCR and histology	4	8.5
Total	47	100.0

Sensitivity and specificity of rapid urease test, histology, *ureC* gene PCR and culture for detection of *H. pylori* infection were calculated, considering case definition of *H. pylori* positive cases as gold standard (table II).

H. pylori was detected by culture only in 10 cases. Metronidazole and levofloxacin exhibited 30.0% resistance, whereas, clarithromycin resistance was 20.0%. All isolated *H. pylori* were sensitive to amoxicillin (table III).

Out of total 143 dyspeptic patients, 71(49.7%) were female and 72(50.3%) were male. Among the study population, male female ratio (1.00: 1.01) was almost equal. Among *H. pylori* positive cases 22(46.8%) were male and 25(53.2%) were female, so the male female ratio in *H. pylori* positive cases was 1.00: 1.14.

The age of the patients range from 18-65 years, with the mean age 42.3 ± 14.3 years. The highest rate of *H. pylori* infection was found in the age group from 41-50 years (25.5%), while the lowest percentage of *H. pylori* infection (4.3%) was in the age group <20 years.

Histopathological examination of gastric mucosa revealed the highest number, 101(70.6%) patients had chronic gastritis among them 31(30.7%) were *H. pylori* positive. Whereas, only nine (6.3%) had duodenal ulcers amid five (55.5%) were *H. Pylori* positive. Among four intestinal metaplasia, 19 gastric ulcers, three adenocarcinomas, and seven normal gastric mucosa cases 50%, 39.8%, 33.3%, and 14.3% were *H. pylori* positive respectively.

Table II: Sensitivity and specificity of RUT, histology, *ureC* gene PCR and culture for detection of *H. pylori* infection

Detection methods	Sensitivity%	Specificity%	PPV%	NPV%	Accuracy%
RUT	91.5	77.0	65.1	95.1	83.9
Histology	74.5	98.9	97.2	88.8	90.1
<i>ureC</i> gene PCR	89.4	100	100	95.0	96.5
Culture*	28.5	100	100	73.4	75.9

*Cultures for *H. pylori* could not be done in 39 cases as the samples were not properly collected and transported for culture.

Table III: Antimicrobial susceptibility pattern of *H. pylori* isolates by disk diffusion method (n=10)

Antimicrobial agents	Sensitiven (%)	Resistantn (%)
Clarithromycin	8 (80.0)	2 (20.0)
Levofloxacin	7 (70.0)	3 (30.0)
Metronidazole	7 (70.0)	3 (30.0)
Amoxicillin	10 (100.0)	0 (0)

Discussion

Among 143 dyspeptic patients, 47 (32.9%) case were classified as *H. pylori* positive cases according to case definition of this study. This finding correlate with Niknam *et al* who reported 31% *H. pylori* positivity among adult dyspeptic population in Iran.³¹ Aftab *et al* reported 47% *H. pylori* infection in adult dyspeptic patients in Bangladesh.³² Several studies from Asian and Middle East countries reported declining *H. pylori* infection with improvement of hygienic condition.^{33, 34} In present study, highest rate of *H. pylori* infection was found in the age group from 41-50 years (25.5%), similar to Helaly *et al*, who also found highest percentage of *H. pylori* infection in the age group from 41-50 years.³⁵

Considering the case definition of *H. pylori* positive case as gold standard, *ureC* gene PCR showed 89.4% sensitivity and 100% specificity. Similar finding was reported by Khalifehgholi *et al* who reported sensitivity and specificity of *ureC* gene PCR 93.5% and 95.6% respectively.³⁶ Low density of *H. pylori* (fewer than 50 bacteria) on biopsy sample, presence of PCR inhibitory substance such as Taq polymerase, prolonged transportation or storage of sample at room temperature may produce misleading results with direct PCR from gastric mucosa.^{25, 37} In this study, RUT and histology had 91.5% and 74.5% sensitivity and 77.0% and 98.9% specificity respectively. Closely similar finding were reported by Khalifehgholi *et al* who had reported 95.6%, 93.5% sensitivity and 100%, 77.8% specificity for RUT and Histology respectively in Iran.³⁶ Sensitivity of those tests varies with the number of biopsies obtained, localization of specimen, expertise of the pathologists, use of PPI and antibiotics.^{8, 38}

In present study, culture showed 100% specificity but low sensitivity (28.5%). Wani *et al* reported sensitivity and specificity of culture to be 13.7% and 100% respectively for detection of *H. pylori* which coincide with this study.³⁹ Sensitivity of culture where higher 92.1% and 100% specific in another study of Aftab *et al*.³² Fluctuation in sensitivity of culture may be explained by the absence or lower density of bacterium in the biopsy specimens, use of antimicrobials, fastidiousness of *H. pylori* or inappropriate conditions of transport.^{8,40}

In this study, only 30% metronidazole resistance was observed by disk diffusion method. However, the higher incidence of 50%-80% metronidazole-resistant strains observed in other studies of developing countries.^{41, 42}

In the present study, all isolated *H. pylori* were sensitive to amoxicillin. Similar finding was reported

by Miftahussurur *et al*, who reported 100% amoxicillin sensitivity.⁴³

Aftab *et al* and Islam *et al*, were also reported 3.6% and 7.3% amoxicillin resistance respectively in Bangladesh.^{21, 23}

Clarithromycin resistance rate was 20%, this result was consistency with Gehlot *et al* and Sun *et al* in which resistance to clarithromycin were 11.8% and 20.7% respectively.^{44,45} Aftab *et al* reported higher resistance rate of clarithromycin (39.3%) detected by agar dilution method.²¹

In present study, 30% levofloxacin resistance was observed, which coincide with the study of Miftahussurur *et al* who reported 42.9 % levofloxacin resistance. High prevalence (66.1%) of levofloxacin resistance was reported by Aftab *et al*.^{43, 21}

Conclusion

Findings of this study demonstrated that, most sensitive methods for the detection of *H. pylori* infection were rapid urease test and *ureC* gene PCR. Clarithromycin and levofloxacin resistance rate were high in Bangladesh. Although, MIC of clarithromycin and levofloxacin by agar dilution method was not be measured as per CLSI guideline, as it is costly and difficult to perform. However, future multicentre studies on a large scale with a full characterisation of *H. pylori* isolates are required to detect the prevalence of *H. pylori* resistance to commonly prescribed antimicrobials to confirm our findings and construct proper strategies to control or eradicate *H. pylori* infection.

Acknowledgments

Authors are grateful to all the faculty members of Department of Microbiology, BSMMU. Authors also thankful to those patients who participated in the study.

Conflict of interests: There was no conflict of interest

Funding: Bangladesh Medical Research Council (BMRC)

Ethical approval: Bangladesh Medical Research Council (BMRC)

Submitted: 06 December 2020

Final revision received: 10 March 2022

Accepted: 20 March 2022

Published: 01 April 2022

Reference

1. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clinical Microbiology Reviews*. 2006;19:449-90. DOI: 10.1128/CMR.00054-05
2. Mapel D, Roberts M, Overhiser A, Mason A. The Epidemiology, Diagnosis, and Cost of Dyspepsia and *Helicobacter pylori* Gastritis: A Case–Control Analysis in the Southwestern United States. *Helicobacter*. 2013;18:54-65. DOI: 10.1111/j.1523-5378.2012.00988.x
3. Srinivas Y, Prasad PK, Sai ND. Prevalence and impact of *Helicobacter pylori* in dyspepsia. *International Surgery Journal*. 2016;3:305-9. DOI: 10.18203/2349-2902.isj20160248
4. Matsuhisa T, Aftab H. Observation of Gastric Mucosa in Bangladesh, the Country with the Lowest Incidence of Gastric Cancer, and Japan, the Country with the Highest Incidence. *Helicobacter*. 2012;17:396-401. DOI: 10.1111/j.1523-5378.2012.00967.x
5. Chisholm SA, Owen RJ. Application of polymerase chain reaction-based assays for rapid identification and antibiotic resistance screening of *Helicobacter pylori* in gastric biopsies. *Diagnostic Microbiology and Infectious Disease*. 2008;61:67-71. DOI: 10.1016/j.diagmicrobio.2007.12.005
6. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al., Second Asia–Pacific consensus guidelines for *Helicobacter pylori* infection. *Journal of Gastroenterology and Hepatology*. 2009;24:1587-600. DOI: 10.1111/j.1440-1746.2009.05982.x
7. Krogfelt KA, Lehours P, Mégraud F. Diagnosis of *Helicobacter pylori* infection. *Helicobacter*. 2005;10:5-13. DOI: 10.1111/j.1523-5378.2005.00341.x
8. Mégraud F, Lehours P. *Helicobacter pylori* detection and antimicrobial susceptibility testing. *Clinical Microbiology Reviews*. 2007;20:280-322. DOI: 10.1128/CMR.00033-06
9. Calvet X, Sánchez-Delgado J, Montserrat A, Lario S, Ramírez-Lázaro MJ, Quesada M, et al., Accuracy of diagnostic tests for *Helicobacter pylori*: a reappraisal. *Clinical Infectious Diseases*. 2009;48:1385-91. DOI: 10.1086/598198
10. Redéen S, Petersson F, Törnkrantz E, Levander H, Mårdh E, Borch K. Reliability of diagnostic tests for *Helicobacter pylori* infection. *Gastroenterology Research and Practice*. 2011;2011. DOI: 10.1155/2011/940650
11. Ricci C, Holton J, Vaira D. Diagnosis of *Helicobacter pylori*: invasive and non-invasive tests. *Best Practice & Research Clinical Gastroenterology*. 2007;21:299-313. DOI: 10.1016/j.bpg.2006.11.002
12. Lu JJ, Perng CL, Shyu RY, Chen CH, Lou Q, Chong SK, Lee CH. Comparison of Five PCR Methods for Detection of *Helicobacter pylori* DNA in Gastric Tissues. *Journal of Clinical Microbiology*. 1999;37:772-4. DOI: 10.1128/JCM.37.3.772-774.1999
13. Chattopadhyay S, Patra R, Ramamurthy T, Chowdhury A, Santra A, Dhali GK, et al., Multiplex PCR assay for rapid detection and genotyping of *Helicobacter pylori* directly from biopsy specimens. *Journal of Clinical Microbiology*. 2004;42:2821-4. DOI: 10.1128/JCM.42.6.2821-2824.2004
14. Oleastro M, Ménard A, Santos A, Lamouliatte H, Monteiro L, Barthélémy P, et al., Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in *Helicobacter pylori*. *Journal of Clinical Microbiology*. 2003;41:397-402. DOI: 10.1128/JCM.41.1.397-402.2003
15. Mishra S, Singh V, Rao G, Jain AK, Dixit VK, Gulati AK, et al., Detection of *Helicobacter pylori* in stool specimens: comparative evaluation of nested PCR and antigen detection. *The Journal of Infection in Developing Countries*. 2008;2:206-10. DOI: 10.3855/jidc.264
16. Hasan M. Dyspepsia in primary care practice in Bangladesh. *Bangladesh Medical Journal*. 2013;42:63-9. DOI: 10.3329/bmj.v42i2.18989
17. Malfertheiner P, Megraud F, O'morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al., Management of *Helicobacter pylori* infection—the Maastricht V/Florence consensus report. *Gut*. 2017;66:6-30. DOI: 10.3329/bmj.v42i2.18989
18. Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of *Helicobacter pylori* in central Gujarat. *Indian Journal of Medical Microbiology*. 2014;32:408. DOI: 10.4103/0255-0857.142256
19. Khan A, Farooqui A, Manzoor H, Akhtar SS, Quraishy MS, Kazmi SU. Antibiotic resistance and *cagA* gene correlation: a looming crisis of *Helicobacter pylori*. *World Journal of Gastroenterology*. 2012;18:2245. DOI: 10.3748%2Fwjg.v18.i18.2245
20. Das R, Sureshkumar S, Sreenath GS, Kate V. Sequential versus concomitant therapy for eradication of *Helicobacter Pylori* in patients with perforated duodenal ulcer: A randomized trial. *Saudi journal of gastroenterology: Official Journal of the Saudi Gastroenterology Association*. 2016;22:309-15. DOI: 10.4103/1319-3767.187605
21. Aftab H, Miftahussurur M, Subsomwong P, Ahmed F, Khan AA, Yamaoka Y. *Helicobacter pylori* antibiotic susceptibility patterns in Bangladesh: Emerging levofloxacin resistance. *The Journal of Infection in Developing Countries*. 2016;10:245-53. DOI: 10.3855/jidc.7713
22. Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, et al., Diagnosis of *Helicobacter pylori* infection: Current options and developments. *World Journal of Gastroenterology*. 2015;21:11221. DOI:10.3748%2Fwjg.v21.i40.11221
23. Islam MM, Nahar S, Sarker MN, Salimullah AS, Rahman MA, Ahmed DS, et al., Antimicrobial Sensitivity Pattern of *Helicobacter pylori* Isolates among Subgroup of Bangladeshi Patients. *Faridpur Medical College Journal*. 2013;8:49-52. DOI: 10.3329/fmcj.v8i2.20280
24. Tongtawee T, Dechsukhum C, Leeansaksiri W, Kaewpitoon S, Kaewpitoon N, Loyd RA, et al., Improved

- Detection of *Helicobacter pylori* Infection and Premalignant Gastric Mucosa Using. *Asian Pacific Journal of Cancer Prevention*. 2016;16:8487-90.
DOI: 10.7314/APJCP.2015.16.18.8487
25. Lage AP, Godfroid E, Fauconnier A, Burette A, Butzler JP, Bollen A, et al., Diagnosis of *Helicobacter pylori* infection by PCR: comparison with other invasive techniques and detection of *cagA* gene in gastric biopsy specimens. *Journal of Clinical Microbiology*. 1995;33:2752-6.
 26. Lascols C, Lamarque D, Costa JM, Copie-Bergman C, Le Glaunec JM, Deforges L, et al., Fast and accurate quantitative detection of *Helicobacter pylori* and identification of clarithromycin resistance mutations in *H. pylori* isolates from gastric biopsy specimens by real-time PCR. *Journal of Clinical Microbiology*. 2003;41:4573-77.
DOI: 10.1128/JCM.41.10.4573-4577.2003
 27. Ndip RN, MacKay WG, Farthing MJ, Weaver LT. Culturing *Helicobacter pylori* from clinical specimens: review of microbiologic methods. *Journal of Pediatric Gastroenterology and Nutrition*. 2003;36:616-22.
 28. McNulty C, Owen R, Tompkins D, Hawtin P, McColl K, Price A, et al., *Helicobacter pylori* susceptibility testing by disc diffusion. *Journal of Antimicrobial Chemotherapy*. 2002;49:601-09.
DOI: 10.1093/jac/49.4.601
 29. Bouihat N, Burucoa C, Benkirane A, Seddik H, Sentissi S, Al Bouzidi A, et al., *Helicobacter pylori* primary antibiotic resistance in 2015 in Morocco: a phenotypic and genotypic prospective and multicenter study. *Microbial Drug Resistance*. 2017 ;23:727-32.
DOI: 10.1089/mdr.2016.0264
 30. Mishra KK, Srivastava S, Garg A, Ayyagari A. Antibiotic susceptibility of *Helicobacter pylori* clinical isolates: comparative evaluation of disk-diffusion and E-test methods. *Current microbiology*. 2006;53:329.
DOI: 10.1007/s00284-006-0143-1
 31. Niknam R, Seddigh M, Fattahi MR, Dehghanian A, Mahmoudi L. Prevalence of *Helicobacter pylori* in patients with dyspepsia. *Jundishapur Journal of Microbiology*. 2014;7:e12676.
DOI: 10.5812/jjm.12676
 32. Aftab H, Yamaoka Y, Ahmed F, Khan AA, Subsomwong P, Miftahussurur M, et al., Validation of diagnostic tests and epidemiology of *Helicobacter pylori* infection in Bangladesh. *The Journal of Infection in Developing Countries*. 2018;12:305-12.
DOI: 10.3855/jidc.9841
 33. Chen J, Bu XL, Wang QY, Hu PJ, Chen MH. Decreasing seroprevalence of *Helicobacter pylori* infection during 1993–2003 in Guangzhou, southern China. *Helicobacter*. 2007;12:164-69.
DOI: 10.1111/j.1523-5378.2007.00487.x
 34. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, et al., Seroprevalence of *Helicobacter pylori* in south Korea. *Helicobacter*. 2007;12:333-40.
DOI: 10.1111/j.1523-5378.2007.00504.x
 35. Helaly GF, El-Afandy NM, Hassan AA, Dowidar NL, Sharaf SM. Diagnostic value of housekeeping [*glmM*] gene expression in antral biopsies in comparison to rapid urease test and histological detection of *Helicobacter Pylori* infection. *Egypt J Med Microbiol*. 2009;18:119-30.
 36. Khalifehgholi M, Shamsipour F, Ajhdarkosh H, Daryani NE, Pourmand MR, Hosseini M, et al. Comparison of five diagnostic methods for *Helicobacter pylori*. *Iranian Journal of Microbiology*. 2013;5:396.
DOI: ncbi.nlm.nih.gov/pubmed/25848511
 37. Thoreson AC, Borre M, Andersen LP, Jørgensen F, Kiilerich S, Scheibel J et al *Helicobacter pylori* detection in human biopsies: a competitive PCR assay with internal control reveals false results. *FEMS Immunology & Medical Microbiology*. 1999;24: 201-8.
DOI:10.1111/j.1574-695X.1999.tb01283.x
 38. PORRO GB. Is routine histological evaluation an accurate test for *Helicobacter pylori* infection? *Alimentary Pharmacology & Therapeutics*. 1999;13:327-31.
DOI: 10.1046/j.1365-2036.1999.00469.x
 39. Wani FA, Bashir G, Khan MA, Zargar SA, Rasool Z, Qadri Q. Antibiotic resistance in *Helicobacter pylori*: a mutational analysis from a tertiary care hospital in Kashmir, India. *Indian Journal of Medical Microbiology*. 2018;36:265.
DOI: 10.4103/ijmm.IJMM_18_19
 40. Kisa O, Albay A, Mas MR, Celasun B, Doganci L. The evaluation of diagnostic methods for the detection of *Helicobacter pylori* in gastric biopsy specimens. *Diagnostic Microbiology and Infectious Disease*. 2002;43:251-5.
 41. Nahar S, Mukhopadhyay AK, Khan R, Ahmad MM, Datta S, Chattopadhyay S, et al., Antimicrobial susceptibility of *Helicobacter pylori* strains isolated in Bangladesh. *Journal of Clinical Microbiology*. 2004;42:4856-8.
DOI: 10.1128/JCM.42.10.4856-4858.2004
 42. Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, et al., Increasing Multidrug Resistance in *Helicobacter pylori* Strains Isolated from Children and Adults in Mexico. *Journal of Clinical Microbiology*. 2001;39:2677-80.
DOI: 10.1128/JCM.39.7.2677-2680.2001
 43. Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging *Helicobacter pylori* levofloxacin resistance and novel genetic mutation in Nepal. *BMC Microbiology*. 2016;16:256.
DOI: 10.1186/s12866-016-0873-6
 44. Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, et al., Low prevalence of clarithromycin-resistant *Helicobacter pylori* isolates with A2143G point mutation in the 23S rRNA gene in North India. *Journal of Global Antimicrobial Resistance*. 2016;6:39-43.
DOI: 10.1016/j.jgar.2016.02.007
 45. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, et al. *World Journal of Gastroenterology*. 2010;16:5118.
DOI: 10.3748/wjg.v16.i40.5118